{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-017568","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2024-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.067614+00:00","generated_at":"2026-06-05T22:09:30.416286+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CRISPR Therapeutics 2023: CASGEVY approved in 5 countries; Q4 net income $89.3M","bullets":["CASGEVY (exa-cel) approved in U.S., EU, Great Britain, Bahrain, KSA for SCD and TDT; ~35,000 patients in U.S. and Europe.","Q4 net income $89.3M vs net loss $110.6M in Q4 2022; cash $1.7B at year-end, pro-forma >$2.1B after $200M milestone and $280M offering.","Clinical trials ongoing for next-gen CAR T (CTX112, CTX131) and in vivo programs (CTX310, CTX320); CTX112 trial in SLE planned H1 2024.","R&D expenses $95.1M in Q4 (down from $103.6M), G&A $16.5M (down from $21.2M); collaboration expense net $20M.","Vertex paid $170M in 2023 milestones; eligible for additional $160M milestones plus royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-017568","json":"https://secwatch.observer/filing/0000950170-24-017568.json","markdown":"https://secwatch.observer/filing/0000950170-24-017568.md","text":"https://secwatch.observer/filing/0000950170-24-017568.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017024017568/0000950170-24-017568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017024017568/crsp-20240221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T22:09:30.416286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03770575f5bc9b1694d4ba16b77774a4d54325d4","claim":"CRISPR Therapeutics AG reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On February 21, 2024, CRISPR Therapeutics AG announced its financial results for the year ended December 31, 2023 and other business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000095017024017568/0000950170-24-017568-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6c25b00765632584f09a406e1c8332b67519d2d9","claim":"CRISPR Therapeutics AG reported financial results for the fourth quarter ended December 31, 2023.","evidence_excerpt":"CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000095017024017568/0000950170-24-017568-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}